抗肿瘤抗生素药物制剂的研究进展  

Recent advances in the drug formulations of anti-tumor antibiotics

作　　者：刘薇 陈丽青 辛欣 黄伟 高钟镐 LILT Wei;CHEN Li-qing;XIN Xin;HUANG Wei;GAO Zhong-gao(State Key Laboratory of Bioaetive Substance and Function of Natural Medicines, Institute of Materia Medica Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing 100050, China)

机构地区：[1]中国医学科学院药物研究所,天然药物活性物质与功能国家重点实验室,北京100050

出　　处：《药学学报》2018年第6期865-877,共13页Acta Pharmaceutica Sinica

基　　金：中国医学科学院医学与健康科技创新工程重大协同创新项目(CAMS-2017-I2M-1-011); 协和青年科研基金和中央高校基本科研业务费专项资金(2017350003)

摘　　要：抗肿瘤抗生素在抗肿瘤方面具有巨大的应用潜力,目前已有一些药物被成功开发,成为临床一线抗肿瘤用药,但抗肿瘤抗生素普遍存在水溶性低、稳定性差和全身毒副作用大等问题。选择合适的递送载体设计合理的递送系统尤其是智能递送系统,可以提高药物的靶向性和疗效,降低药物的不良反应。本文对抗肿瘤抗生素递送的载体及递送系统的研究进展进行了综述,包括现已上市的抗肿瘤抗生素药物制剂、处于临床研究阶段的抗肿瘤抗生素药物制剂和处于基础研究阶段的新型抗肿瘤抗生素药物制剂。Anti-tumor antibiotics exhibit great application potential in the anti-tumor therapy. Some drugs have become the first-line medication clinically. However, there are always various problems associated with anti-tumor antibiotics, such as poor solubility and instability as well as severe systemic side effects. It is important to choose suitable delivery carriers for a reasonable delivery system for a good targeting ability, enhanced anti-tumor efficacy and reduced adverse effects of the anti-tumor antibiotics, especially in the smart delivery systems. This review summarizes the carriers and the advances in the delivery systems of anti-tumor antibiotics, including anti-tumor antibiotic drugs currently on the market, in the clinical research stage and in the basic research stage.

关 键 词：抗肿瘤抗生素 药物载体 智能递送系统 靶向性 

分 类 号：R943[医药卫生—药剂学]